Beta-Blockers for Anxiety: What the Evidence Actually Supports

Propranolol for anxiety is one of those treatments that is prescribed far more often than it has been studied. The off-label use is enormous — particularly for performance anxiety — but the evidence base is surprisingly thin.

What beta-blockers do

Beta-blockers block beta-adrenergic receptors, reducing the effects of adrenaline (epinephrine) on the body. The relevant effects for anxiety are peripheral: reduced heart rate, reduced tremor, reduced sweating, and reduced sensation of pounding heart.

Propranolol is the most commonly used for anxiety because it crosses the blood-brain barrier (unlike more selective beta-blockers like atenolol), potentially having some central effects as well. But the clinical effect on anxiety appears to be primarily through reducing the physical symptoms.

Performance anxiety: where the story starts

The use of beta-blockers for anxiety began in the 1960s–70s, largely with musicians and performers. An early trial found that oxprenolol (a beta-blocker) reduced tremor and improved performance quality in musicians with stage fright [2].

This finding mapped onto an intuitive model: physical symptoms (shaking hands, racing heart) cause performance impairment, which increases anxiety, which worsens symptoms — a cycle that beta-blockers break at the physical step.

For this narrow indication, the evidence is reasonable but based on small trials, mostly from the 1970s–80s. Performance anxiety in musicians and speakers who are impaired primarily by physical symptoms is probably where beta-blockers work best. But even here, the evidence quality is modest by modern standards [5].

Beyond performance: the evidence weakens

A systematic review and meta-analysis examined the broader evidence for beta-blockers across anxiety disorders. Across 12 trials, the overall effect was small and not statistically significant [1]. This is a striking finding given how widely propranolol is prescribed for anxiety.

Generalized anxiety disorder. The evidence does not support beta-blockers for GAD. SSRIs, SNRIs and CBT have far more evidence, and guidelines do not recommend beta-blockers as a treatment.

Social anxiety disorder. NICE guidelines for social anxiety explicitly note that the evidence for beta-blockers in social anxiety disorder is insufficient and do not recommend them [4]. The distinction between “performance-only” social anxiety (where beta-blockers may help with physical symptoms) and broader social anxiety disorder (where the core problem is fear of negative evaluation, not tremor) is clinically important.

Panic disorder. No convincing evidence supports beta-blockers for panic disorder. The physical symptoms of panic (palpitations, breathlessness) are partly driven by mechanisms beyond beta-adrenergic activation.

The prescribing-evidence gap

The widespread use of propranolol for anxiety illustrates a common pattern in medicine: a treatment that works in a narrow context gets generalized to broader use based on clinical experience rather than trial evidence. Doctors observe that patients report feeling calmer on propranolol, patients request it because it helped a friend, and the treatment is low-risk enough that the prescription seems reasonable.

This may be fine in practice — propranolol has a relatively benign side-effect profile for most people — but it means many people are taking a medication whose evidence base for their specific type of anxiety is weak. The placebo response in anxiety is substantial, and without controlled evidence, it’s hard to know how much of the benefit is pharmacological versus expectation.

The memory reconsolidation angle

A separate line of research has explored whether propranolol can disrupt fear memory reconsolidation — essentially weakening fearful memories when they are reactivated. This has generated excitement but mixed results in humans. A study found that propranolol did not impair fear extinction in humans in the way animal studies predicted [6]. This research is at an early stage and does not support clinical use for anxiety treatment.

Questions to ask about beta-blocker claims

1. Is the evidence for the specific type of anxiety (performance, social, generalized)?
2. Are the outcomes physical symptoms, subjective anxiety, or both?
3. How large and rigorous are the trials?
4. Is the claim based on controlled evidence or clinical anecdote?
5. How does the evidence compare with established first-line treatments?

What remains uncertain

Whether propranolol works better for people whose anxiety is primarily driven by physical symptoms (somatic anxiety) versus cognitive symptoms (worry, rumination) has not been formally tested. Whether the as-needed pattern of use (take before a specific situation) is more effective than regular dosing for situational anxiety needs modern, well-powered trials. And whether the widespread off-label prescribing is doing more good than harm — or whether patients might benefit more from evidence-based alternatives — is a legitimate question that the current data cannot answer.

Considering beta-blockers. If you’re using or considering propranolol for anxiety, discuss it with your prescriber. It may help with physical symptoms in specific situations but is not a general anxiety treatment. Don’t stop prescribed medication without medical advice. If anxiety is affecting your daily life, talk to a GP or mental health professional. If you are in crisis or thinking about harming yourself, contact emergency services or a crisis line now: in the US, call or text 988; in the UK and Ireland, Samaritans on 116 123.